Expert Interview
Discussing the use of PLUVICTO to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.
Ticker(s): NVSInstitution: Arizona Center for Cancer Care
- Currently manages ~100 prostate cancer pts/yr
- Familiar with PNT2002 and its Phase 3 study data
- A board-certified radiation oncologist and has expertise in the management of breast, prostate and gastrointestinal cancers.
- A member of the American Society for Therapeutic Radiology and Oncology, American Brachytherapy Society, American College of Radiology and the Arizona Radiological Society.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
